Robert Martin
9Patents
4h-index
7Co-inventors
42Inventor score
Filing activity: Jun 21, 2011 → Jun 19, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9381181B2 | Treatment of NAFLD and NASH | Human Necessities | 29 | Active |
| US9616039B2 | Treatment of NAFLD and NASH | Human Necessities | 25 | Active |
| US10188620B2 | Treatment for NAFLD and NASH | Human Necessities | 7 | Active |
| US9962346B2 | Treatment of NAFLD and NASH | Human Necessities | 6 | Active |
| US10342770B2 | Treatment of NAFLD and NASH | Human Necessities | 3 | Active |
| US10722483B2 | Treatment of NAFLD and NASH | Human Necessities | 1 | Active |
| US9241924B2 | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine | Human Necessities | 0 | Active |
| US11179359B2 | Treatment of NAFLD and NASH | Human Necessities | 0 | Active |
| US10098843B2 | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.